ArticleCancers2010
Markers for detection of prostate cancer.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Urinary endogenous peptides as biomarkers for prostate cancer.Oncology letters · 2023Article
- Comprehensive biomarker profiles and chemometric filtering of urinary metabolomics for effective discrimination of prostate carcinoma from benign hyperplasia.Scientific reports · 2022Article
- siRNA Mediate RNA Interference Concordant with Early On-Target Transient Transcriptional Interference.Genes · 2021Article
- Template-Assisted Plasmonic Nanogap Shells for Highly Enhanced Detection of Cancer Biomarkers.International journal of molecular sciences · 2021Article
- Identification of plasma lipid species as promising diagnostic markers for prostate cancer.BMC medical informatics and decision making · 2020Article
- Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation.Prostate international · 2017Article
- Computational Methods and Correlation of Exon-skipping Events with Splicing, Transcription, and Epigenetic Factors.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers.Prostate international · 2016Article
- A novel three serum phospholipid panel differentiates normal individuals from those with prostate cancer.PloS one · 2014Article
- Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients.Journal of translational medicine · 2011Article
- Metabolomics: a novel approach to early and noninvasive prostate cancer detection.Korean journal of urology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early detection of prostate cancer is problematic, not just because of uncertainly whether a diagnosis will benefit an individual patient, but also as a result of the imprecise and invasive nature of establishing a diagnosis by biopsy. Despite its low sensitivity and specificity for identifying patients harbouring prostate cancer, serum prostate specific antigen (PSA) has become established as the most reliable and widely-used diagnostic marker for this condition. In its wake, many other markers have been described and evaluated. This review focuses on the supporting evidence for the most prominent of these for detection and also for predicting outcome in prostate cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.